As of 2025-07-12, the Intrinsic Value of Cymabay Therapeutics Inc (CBAY) is (21.67) USD. This CBAY valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 32.48 USD, the upside of Cymabay Therapeutics Inc is -166.70%.
The range of the Intrinsic Value is (95.95) - (12.37) USD
Based on its market price of 32.48 USD and our intrinsic valuation, Cymabay Therapeutics Inc (CBAY) is overvalued by 166.70%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (95.95) - (12.37) | (21.67) | -166.7% |
| DCF (Growth 10y) | (13.13) - (92.70) | (22.07) | -167.9% |
| DCF (EBITDA 5y) | (7.29) - (10.61) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (8.91) - (13.02) | (1,234.50) | -123450.0% |
| Fair Value | -4.59 - -4.59 | -4.59 | -114.13% |
| P/E | (17.75) - (16.93) | (17.72) | -154.5% |
| EV/EBITDA | (8.98) - (8.13) | (9.20) | -128.3% |
| EPV | (4.84) - (7.36) | (6.10) | -118.8% |
| DDM - Stable | (12.19) - (118.01) | (65.10) | -300.4% |
| DDM - Multi | (10.41) - (80.22) | (18.59) | -157.2% |
| Market Cap (mil) | 3,728.38 |
| Beta | 0.93 |
| Outstanding shares (mil) | 114.79 |
| Enterprise Value (mil) | 3,631.48 |
| Market risk premium | 4.60% |
| Cost of Equity | 6.99% |
| Cost of Debt | 5.00% |
| WACC | 6.89% |